Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2 –Positive Metastatic Breast Cancer From the US and Chinese Perspectives
Conclusion: In the United States and China, tucatinib combined with trastuzumab and capecitabine is not cost-effective for patients with HER-2 positive metastatic breast cancer.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | HER2 | Herceptin | Study | USA Health | Xeloda